Takeda Pharmaceutical (NYSE:TAK) Insider Sells $1,162,395.30 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Platford sold 55,617 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $20.90, for a total transaction of $1,162,395.30. Following the completion of the sale, the insider owned 270,253 shares of the company’s stock, valued at approximately $5,648,287.70. The trade was a 17.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Giles Richard Platford also recently made the following trade(s):

• On Monday, August 10th, Giles Platford sold 31,083 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $531,519.30.

Takeda Pharmaceutical Trading Down 0.8%

Shares of TAK opened at $21.02 on Friday. Takeda Pharmaceutical Co. has a 12-month low of $13.56 and a 12-month high of $21.73. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $67.35 billion, a price-to-earnings ratio of 27.65 and a beta of -0.02. The stock’s 50-day moving average price is $19.12 and its 200 day moving average price is $17.67.

Hedge Funds Weigh In On Takeda Pharmaceutical

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its stake in Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after buying an additional 370,800 shares in the last quarter. Quantinno Capital Management LP raised its stake in Takeda Pharmaceutical by 20.6% during the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after acquiring an additional 219,999 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after acquiring an additional 60,725 shares during the period. Bleakley Financial Group LLC lifted its holdings in shares of Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after acquiring an additional 68,844 shares during the period. Finally, Ethic Inc. boosted its stake in shares of Takeda Pharmaceutical by 19.5% in the 3rd quarter. Ethic Inc. now owns 436,514 shares of the company’s stock valued at $7,940,000 after purchasing an additional 71,261 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on TAK. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings raised shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.

The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Takeda serves patients and healthcare providers in Japan and markets around the world.